NPN Application Requirements: Why Health Canada Issues a Notice of Deficiency (And How to Avoid It)

Canada’s natural health products industry generates roughly $2.8 billion CAD annually, and every product sold legally on a shelf here carries an eight-digit NPN — a Natural Product Number issued by Health Canada after a reviewed Product Licence Application. Getting that number sounds straightforward. The Natural Health Products Regulations (SOR/2003-196), in force since January 2004, set out exactly what you need to submit. And yet, a substantial proportion of applications come back with a Notice of Deficiency before they ever reach approval.

A Notice of Deficiency isn’t a rejection. But it isn’t good news, either. It stops your application clock, adds weeks or months to your timeline, and sometimes requires re-testing that wasn’t in your original budget. In our work supporting manufacturers and importers through the NPN process, we’ve seen the same failure points appear again and again — and almost all of them are preventable with better preparation upfront.

What the NHPD Actually Reviews (And in What Order)

When your Product Licence Application (PLA) lands at the Natural Health Products Directorate, it’s classified into one of three review streams before anyone reads your evidence file. Class I applications — those relying on a Health Canada-approved monograph with no deviations — carry a 60-day review target. Class II applications, which reference pre-assessed evidence or published literature, are assigned a 180-day target. Class III applications covering novel or non-referenced evidence can take up to 300 days under current service standards.

That classification alone determines your launch window. Most applicants want to be in Class I. But a surprising number submit a Class I application and inadvertently trigger a Class II review by deviating from the approved monograph — changing the dosage form, target population, or duration without using a proper reference. That deviation is often the first point of failure, and it’s entirely invisible to applicants who haven’t read the monograph carefully against their own formulation.

If your claim or formulation doesn’t map cleanly to an existing entry in Health Canada’s Compendium of Monographs, build your submission as a Class II from the start. Don’t force a monograph fit to get a faster clock. The Directorate will catch it, and the resulting NoD will cost you far more time than the honest classification would have.

The Four Most Common Reasons NPN Applications Get a Notice of Deficiency

The Evidence Doesn’t Match the Claim

This is the most frequent deficiency we encounter. An applicant lists a health claim that the evidence file doesn’t fully support — not because the evidence doesn’t exist, but because the evidence submitted doesn’t match the population, dose, or route of administration specified in the claim.

You can have five peer-reviewed studies supporting a botanical extract’s effect on cardiovascular markers, and still receive a deficiency if those trials enrolled participants with pre-existing cardiovascular conditions while your label claim targets healthy adults seeking “general cardiovascular health support.” The Directorate evaluates the totality of evidence, not just the presence of positive studies.

Under the NHPR, traditional use evidence typically requires documentation spanning at least 50 years of continuous use within a recognized traditional medicine system. Evidence from assessed clinical literature requires a systematic search, a rationale for inclusion and exclusion criteria, and a formal evidence summary document. Submitting PDFs of studies without any synthesis or evaluation layer is a reliable way to generate a deficiency notice — regardless of how strong the underlying science is.

Labelling Non-Compliance Under NHPR Sections 80–101

Health Canada’s labelling requirements under the Natural Health Products Regulations are extensive. A compliant label must display, at minimum: the product’s brand name, medicinal ingredients with their quantity and potency, non-medicinal ingredients, the recommended use or purpose, directions for use, cautions and warnings, the NPN once issued, and the recommended dose — in both English and French, unless you’ve applied for a bilingual exemption available for select Class I products in certain provincial markets.

What trips applicants up isn’t usually a missing element. It’s inconsistency between the label copy and the evidence file. If your evidence submission describes “200 mg of standardized extract containing 5% ginsenosides” and your proposed label reads “200 mg Panax ginseng root extract,” that’s a discrepancy in the Directorate’s eyes — even if the two are botanically equivalent. The reviewer is checking your label against your own submission, and any gap between them generates a deficiency.

Get your proposed label reviewed side-by-side with your evidence file before you submit. That single step eliminates a remarkable number of avoidable deficiency rounds.

Incomplete Quality Summary

Every NPN application requires a quality summary covering the product’s composition, specifications, and manufacturing controls. For finished natural health products, this means: a complete ingredient list with quantities and specifications, a description of the manufacturing process, and confirmation of GMP compliance in accordance with Part 3 of the NHPR or the applicable site licence conditions.

The deficiency we see most consistently in this section is a quality summary that lists ingredient specifications without referencing the testing method used to verify them. Stating “Vitamin C: 500 mg per tablet, specification: 95–105% of stated label claim” is fine as a starting point — but the Directorate expects you to identify which method confirms that specification. USP methods are well-accepted and straightforward to reference. Proprietary analytical methods require supporting validation data, which many applicants haven’t prepared.

For botanical ingredients, Health Canada expects identity testing in addition to potency testing. An assay for marker compounds does not substitute for a validated identity test — a distinction that catches applicants who are accustomed to FDA dietary supplement requirements, where this distinction is handled differently under 21 CFR Part 111.

Site Licence Gaps

Product licensing and site licensing are separate processes under the NHPR, but they’re tightly connected in practice. Canadian manufacturers need a valid Site Licence. If you’re importing a product manufactured abroad, the foreign facility must have undergone a Health Canada GMP assessment, or you need to hold a Site Licence as the importer of record.

Applications stall when the manufacturing site listed on the PLA doesn’t hold a current Site Licence that covers the relevant dosage form or activity type. This happens more than it should, because contract manufacturing relationships are often established months before a submission is prepared — and Site Licence conditions can change in the interim. A facility might narrow its covered dosage forms during a licence renewal without notifying every client. Site licence status is publicly searchable in Health Canada’s databases, but that search needs to happen at the time of submission, not when the original contract was signed.

How to Front-Load Your Application and Reduce Revision Cycles

The most practical step before any NPN submission is a structured internal review against Health Canada’s own submission templates and checklists. The Directorate publishes product-specific application forms, evidence guidance documents, and pre-submission checklists. These aren’t aspirational — they’re the actual framework reviewers use to evaluate your file.

Run your evidence summary, quality specifications, and proposed label through the applicable checklist as a mandatory gate before submission. Assign that review to someone who wasn’t involved in preparing the original submission. They’ll catch the normalizations and inconsistencies that the original drafter stopped seeing weeks ago.

If third-party testing supports your quality summary, verify that your Certificates of Analysis reflect testing performed under ISO/IEC 17025-accredited conditions, or that your contract laboratory’s qualifications are fully documented in the quality file. Health Canada expects analytical data to be traceable to a qualified laboratory. A COA from an unaccredited facility without supporting qualification records is a predictable quality deficiency.

A Note on Timelines: What You Can Realistically Expect

Service standard targets — 60, 180, and 300 days — are targets, not guarantees. Health Canada publishes performance data against those targets in the Natural Health Products Directorate’s annual reports, and actual review timelines vary. Build meaningful buffer into your product launch calendar before committing to retail placement dates or manufacturing runs.

More consequentially, the review clock restarts from zero on each revision round. A single Notice of Deficiency on a Class II application doesn’t add a few weeks — it can add the full 180-day review window to your timeline once you respond and the file re-enters the queue. That’s a material project risk, and it’s one that a thorough pre-submission review will prevent in most cases.

The NPN applications that move through the Directorate cleanly share a common trait: the manufacturer treated the submission like a regulatory dossier. Systematic evidence review, method-referenced quality specifications, bilingual label drafts verified against the evidence file, and a current site licence check — each element takes a few hours upfront. None of them takes as long as a deficiency round-trip.

If your NPN submission is approaching and you want an independent review of your evidence file or quality summary before it goes to the Directorate, that pre-submission assessment is often the highest-value investment in the entire process.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Androxa. Learn more about our team

Talk to our team about Health Canada compliance. Contact us

Related from our network

• ISO 17025-Accredited COA Verification for NHP Ingredients — Qalitex Laboratories provides accredited identity, potency, and purity testing for botanical and synthetic raw materials used in Canadian NHP formulations.
• EU Cosmetics vs. Canadian NHP Licensing: Navigating Two Regulatory Pathways — Care Europe covers the EU 1223/2009 notification process and how it compares when taking a topical health product into European markets.